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Abstract
Background: SLC19A3 (solute carrier family 19, member 3) is a thiamin transporter with 12 transmembrane
domains. Homozygous or compound heterozygous mutations in SLC19A3 cause two distinct clinical phenotypes,
biotin-responsive basal ganglia disease and Wernicke’s-like encephalopathy. Biotin and/or thiamin are effective
therapies for both diseases.
Methods: We conducted on the detailed clinical, brain MRI and molecular genetic analysis of four Japanese
patients in a Japanese pedigree who presented with epileptic spasms in early infancy, severe psychomotor
retardation, and characteristic brain MRI findings of progressive brain atrophy and bilateral thalami and basal
ganglia lesions.
Results: Genome-wide linkage analysis revealed a disease locus at chromosome 2q35-37, which enabled
identification of the causative mutation in the gene SLC19A3. A pathogenic homozygous mutation (c.958G > C,
[p.E320Q]) in SLC19A3 was identified in all four patients and their parents were heterozygous for the mutation.
Administration of a high dose of biotin for one year improved neither the neurological symptoms nor the brain
MRI findings in one patient.
Conclusion: Our cases broaden the phenotypic spectrum of disorders associated with SLC19A3 mutations and
highlight the potential benefit of biotin and/or thiamin treatments and the need to assess the clinical efficacy of
these treatments.
Background
The SLC19 (solute carrier family 19) gene family
(comprising SLC19A1, SLC19A2,a n dSLC19A3)i s
r e s p o n s i b l ef o rt h eu p t a k eo fw a t e r - s o l u b l ev i t a m i n s
into cells. SLC19A1 was first identified as a gene that
could restore reduced folate carrier activity and
methotrexate sensitivity in methotrexate-resistant
human breast cancer cells [1]. SLC19A2 was isolated
as the gene responsible for thiamin-responsive mega-
loblastic anemia syndrome (TRMA; MIM 249270)
[2-4] and was identified as a thiamin transporter [5].
SLC19A3 was cloned based on its homology with
SLC19A1 and SLC19A2, and it was identified as a
second thiamin transporter [6-8]. There are signifi-
cant structural similarities among the three SLC19
proteins at the amino-acid-sequence level (> 39%
identity). All three SLC19 genes encode transporter
proteins composed of 12 transmembrane domains,
a n da l la r ee x p r e s s e du b i q u itously [9]. Two appar-
ently unrelated autosomal recessive disease pheno-
types, biotin-responsive basal ganglia disease (BBGD;
MIM 607483) [10,11] and Wernicke’s-like encephalo-
pathy (MIM 606152) [12], are associated with muta-
tions of SLC19A3. We herein report on a study of
four patients that presented with epileptic spasms in
early infancy, severe psychomotor retardation, and
characteristic brain MRI findings of progressive brain
atrophy and bilateral thalami and basal ganglia
lesions. We found that these phenotypes were caused
by a homozygous SLC19A3 mutation and discuss the
phenotype-genotype correlation of the disorders asso-
ciated with SLC19A3 mutations. * Correspondence: nwaka@inst-hsc.jp
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Case Presentation
The experiments were conducted after approval by the
institutional review boards at the Institute for Develop-
mental Research, Aichi Human Service Center and
Brain Research Institute, Niigata University. Written
informed consent was obtained from the parents of the
four patients participating in this study.
Patient V-2
The proband was an 18-year-old Japanese boy born to
healthy consanguineous parents (Figure 1): his mater-
nal grandmother and father are first cousins. Notably,
his three cousins (Figure 1 patients V-3, V-4, and
V-6) had very similar clinical courses and features.
This patient was born at a gestational age of 38 weeks
without complications. At 1 month of age, he pre-
sented an opisthotonic posture, and at 2.5 months of
age, epileptic spasms appeared. His EEG demon-
strated multifocal spikes but no hypsarrhythmia; thus,
he was diagnosed with atypical infantile spasms
without hypsarrhythmia. A complete blood count,
biochemical analyses for a wide range of metabolic
disorders and an immunohistochemical analysis of
skeletal muscle biopsies were normal. Two courses of
ACTH therapy were performed but were only transi-
ently effective. At 1 year of age, intractable tonic sei-
zures appeared, and he showed severe mental
retardation and spastic quadriplegia with an increased
jaw-jerk reflex and hyperreflexia in the extremities,
including positive Babinski sign. Involuntary move-
ment was not observed. Brain MRI at 4 months of
age revealed symmetrical abnormal intensities in the
bilateral thalami and basal ganglia on T1- and
T2-weighted images (Figure 2A and 2B). Profound
brain atrophy progressed at 1 year (Figure 2C, 2D, 2E
Figure 1 Pedigree and haplotypes in the linkage region. Squares and circles indicate males and females, respectively. The proband and
affected individuals are indicated by an arrow and closed symbols, respectively. Only informative markers that define the genetic breakpoints are
shown. The maximum LOD score was in the region between D2S163 to D2S2344.
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Page 2 of 8Figure 2 MRIs of patients V-2, V-3, V-4 and V-6 at various ages. Areas of abnormal intensity in the thalami and basal ganglia (arrowheads)
were distinct at 4 months in V-2 (A, B). The sagittal and axial views of T1- and T2-weighted images of V-2 at 1 year showed severe brain
atrophy (D, E, F). The sagittal and axial views of T1- and T2-weighted images of V-3 at 7 years, 5 months (G, H, I), V-4 at 6 years, 3 months (J, K,
L), and V-6 at 3 years, 5 months (M, N, O) showed severe brain atrophy, including cerebellar atrophy (I, L, O) and abnormal intensity areas in the
thalami and basal ganglia.
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Page 3 of 8and 2F). At 12 years of age, gastrostomy was per-
formed because of swallowing difficulties. At present,
he is bedridden with contractures of the extremities
and has several tonic seizures daily.
Patient V-3 and Patient V-4
Two other patients who are cousins of patient V-2 and
born to parents who are second cousins also had quite
similar clinical course and brain MRI findings (Figure 2G,
H, I, J, K, L and Table 1). Patients V-3 and V-4 died of
respiratory failure at 12 years and 3 months and 9 years
and 7 months of age, respectively.
Patinet V-6
P a t i e n tV - 6w a sb o r na t4 0w e e k sg e s t a t i o nw i t h o u t
complications. He is the fourth child and the younger
brother of patients V-3 and V-4. At 11 months of age,
he began experiencing epileptic spasms in clusters.
His EEG demonstrated anterior dominant irregular
diffuse spikes and waves, and polyspikes and waves;
however, hypsarrhythmia was not observed. He was
diagnosed with atypical infantile spasms. At 1 year of
age, he was admitted to our hospital for treatment for
epilepsy. He was able to eat weaning food; however,
he did not exhibit head control and was unable to roll
Table 1 Clinical and brain MRI findings of the present patients, BBGD and Wernicke’s-like encephalopathy caused by
SLC19A3 mutations
Patients V-2 V-3 V-4 V-6 BBGD Wernicke’s-like
Present age 18Y 12Y(dead) 9Y(dead) 6Y 9-33Y ND
Sex male male male male male, female male
Consanguinity + + + + +/- -
Neurological findings
bad temper 1M 2M 2M 2M ND ND
head control - - - - + +
opisthotonic posture 1M - 2M 11M ++ -
mental retardation ++ ++ ++ ++ ++ (without treatment) -
dysphagia ++ ++ ++ + + -
pyramidal signs ++ ++ ++ ++ ++ -
quadriplegia ++ ++ ++ ++ ++ -
dystonia - - - - ++ -
cogwheel rigidity - - - - ++ -
ophthalmoplegia - - - - + ++
nystagmus - - - - - ++
ataxia - - - - - ++
Seizure
onset 2M 3M 2M 11M childhood second decade
type ES®SGE ES®SGE ES®SGE ES®PE PE, SGE PE
Gastrostomy 12Y 7Y 6Y - - -
Tracheotomy - 4Y 4Y - - -
Pathologic brain MRI findings 11M 7Y 6Y 14M 3-33Y 36Y
cerebral atrophy ++ ++ ++ ++ - -
cerebellar atrophy ++ + ++ + - -
brain stem atrophy + - - - - -
Abnormal signals in
thalamus + + + + - +
caudate nuclei + + + + + -
putamen + + + + + -
cortical & subcortical region - - - - + -
periaqueductal region - - - - - +
Treatment NP NP NP biotin: ineffective biotin (and thiamin): effective thiamin: effective
Y = year(s); M = month(s); ES = epileptic spasm; SGE = symptomatic generalized epilepsy; PE = partial epilepsy; (+) = presence of clinical signs, + to ++
increasing severity; (-) = minus sign; ND = not described; NP = not performed. Typical clinical and brain MRI findings of BBGD [10,16] and Wernicke’s-like
encephalopathy [12] are summarized.
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Page 4 of 8over. Neurological examination revealed generalized
hypotonia, and deep tendon reflexes of the extremities
were not elevated. ACTH therapy was transiently
effective in alleviating the attacks. Brain MRI at 14
months of age demonstrated severe cortical atrophy
and abnormal intensities in the bilateral thalami and
basal ganglia. Physical examination at 2 years of age
demonstrated severe psychomotor retardation; he was
not able to sit without support and was also unable to
roll over. Neurological examination demonstrated
generalized hypotonia with spasticity of limbs and
severe mental retardation. Involuntary movement was
not observed. Because he was identified as homozy-
gous for a SLC19A3 mutation, patient V-6 had taken
biotin (5 mg/kg/day) for one year beginning at 19
months of age with informed consent from his par-
ents; however, his neurological symptoms and brain
MRI findings did not improve. Brain MRI at 3 years
and 5 months of age demonstrated diffuse brain atro-
phy and abnormal intensities in the bilateral thalami,
caudate nuclei and putamen on T1- and T2-weighted
images (Figure 2M, 2N and 2O). Currently, Patient
V-6, at 6 years of age, is bedridden. The clinical fea-
tures and brain MRI findings of the four patients are
summarized in Table 1.
Genome-Wide Linkage Analysis
We performed a genome-wide linkage analysis in ten
family members related to the four neurological
patients using 763 microsatellite markers (Applied
Biosystems, Foster City, CA) to cover the all auto-
somes with an average interval of 4.6 cM. Multi-point
LOD (logarithm of odds) scores were calculated using
the Allegro program for all loci under the assumption
of autosomal recessive inheritance and a disease fre-
quency of 0.001 [13]. Haplotypes were constructed
manually to minimize the number of recombination
events.
Genetic Analyses
Genomic DNA was isolated from white blood cells by
phenol/chloroform extraction. PCR-amplified DNA frag-
ments were isolated with a QIAEX II Gel Extraction Kit
(QIAGEN, Valencia, CA) and purified using polyethy-
lene glycol (PEG 6000) precipitation. Isolated PCR
products were cloned and sequenced with an SQ5500E
DNA sequencer (HITACHI, Tokyo, Japan), or were
sequenced directly with specific inner primers or the
same primers used for PCR [14].
Construction of Expression Vectors
First-strand cDNA was synthesized by reverse transcrip-
tion of 10 μg of total RNA from normal or the pro-
band’s lymphoblastoid cells using a First-Strand cDNA
Synthesis Kit (GE Healthcare, Tokyo, Japan) with speci-
fic antisense primer (A1: 5’-GTTGCGTCTAGATTA-
GAGTTTTGTTGAC-3’, XbaI site is underlined) in a
reaction volume of 15 μl. The cDNA products were
amplified with LA-Taq DNA Polymerase (TAKARA
BIO INC, Otsu, Japan) using the specific primers (S1:
5’-AACAGACACTCCCTTCTGAATTCATG-3’ and A1,
EcoRI site is underlined). PCR was performed in a
total volume of 20 μl for 36 cycles as follows: dena-
turation at 94°C for 30 s, annealing at 58°C for 30 s,
and extension at 72°C for 90 s. The 1,535-bp PCR pro-
ducts were subcloned into the EcoRI/XbaIs i t e so ft h e
pCI-neo vector, a mammalian expression vector driven
by a cytomegalovirus (CMV) promoter and enhancer,
to generate pCI-neo-SLC19A3(WT) and pCI-neo-
SLC19A3(E320Q).
Thiamin Transport Assay
We performed a thiamin transport assay according to
the protocol of Ashokkumar et al. [15]. Briefly, a 1.0
μg aliquot of the SLC19A3 expression vector (pCI-neo-
SLC19A3(WT), pCI-neo-SLC19A3(E320Q)) and the
control vector (pCI-neo) were transfected into HEK293
cells in 24-well plates using Lipofectamine 2000
Reagent (Invitrogen, Carlsbad, CA). Two days after
transfection, the HEK293 cells were washed two times
with pre-warmed phosphate-buffered saline (PBS) and
incubated for 10 min at 37°C in 200 μlo fa s s a yb u f f e r
(20 mM HEPES (pH 7.4), 140 mM NaCl, 5 mM KCl, 2
mM MgCl2,a n d5m Ms u c r o s e )c o n t a i n i n g0 . 1μMo f
[
3H]-labeled thiamin (14.8 kBq:0.74TBq/mmol) with or
without 0.1 mM unlabeled thiamin. Thiamin transport
was terminated by the addition of 0.5 ml of ice-cold
PBS followed by immediate aspiration. Cells were
rinsed two times with 0.5 ml of ice-cold PBS and lysed
with 200 μl of 0.2 M NaOH for 30 min at 65°C. A
50-μl aliquot of lysate was spotted onto Whatman 3
MM chromatography paper (GE Healthcare), and
radioactivity counts were conducted using a liquid
scintillation counter. Protein concentrations were
estimated using an Advanced Protein Assay Kit (Cytos-
keleton Inc. Denver, CO) according to the manufac-
turer’si n s t r u c t i o n s .
Results
The Disease Maps to Chromosome 2q35-37
The patients’ characteristic clinical features without
obvious extrapyramidal symptoms, rapid clinical course
and brain MRI findings did not lead us to diagnosis a
specific disease. However, we conducted a genome-wide
linkage analysis that revealed a disease locus in the
region from D2S2382 to D2S206 on 2q35-37 (~16.7
Mb) with a maximum multipoint LOD score of 4.75
(Figure 1).
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SLC19A3 gene maps in the region, and then we identi-
fied a homozygous mutation (c.958G > C, [p.E320Q]) in
exon 3 of SLC19A3 in all patients, while their parents
were heterozygous for the mutation (Figure 3A and 3B).
Determination of thiamin transport activity of mutant
SLC19A3 Proteins in HEK293 cells
To address the effect of the E320Q mutation on thiamin
transport activity, we transfected wild-type and mutant
SLC19A3 expression constructs into HEK293 cells. We
then analyzed the uptake of [
3H]-labeled thiamin into
these cells. We found that the E320Q mutation
decreased thiamin uptake to 63% of that of the wild-
type protein (Figure 3C), corroborating the findings of
Kono et al. [12] using Chinese hamster ovary (CHO)
cells.
Discussion
In the present study, we demonstrated that a homozy-
gous mutation (E320Q) in SLC19A3 is associated with
epileptic spasms in early infancy, severe psychomotor
retardation and characteristic MRI findings, including
progressive brain atrophy and bilateral thalami and basal
ganglia lesions. It should be noted that four patients in
this family showed quite similar clinical presentations,
strongly arguing for the distinct genotype-phenotype
correlation associated with the homozygous E320Q
mutation. Two apparently unrelated disease phenotypes,
BBGD (MIM 607483) [10,11] and Wernicke’s-like
Figure 3 Identification and characterization of a disease mutation (c.958G > C, [p.E320Q]). (A) The sequence analyses showed a G to C
substitution at nucleotide position 958 in Exon 3 of SLC19A3, resulting in a substitution of glutamic acid at codon 320 for glutamine (c.958G >
C, [p.E320Q]), indicated by an arrow. (B) RsaI (GTAC)-digested PCR products were run through a 1.2% agarose gel. Digestion of products
containing the E320Q mutation resulted in 357- and 86-bp fragments. All patients (V-2, V-3, V-4 and V-6) were homozygous for the mutation,
and their parents were heterozygous for the mutation. (C) [
3H]-thiamin uptake by HEK293 cells expressing wild-type or E320Q SLC19A3. Two
days after transfection, cells were incubated with 0.1 μMo f[
3H]-labeled thiamin (14.8 kBq:0.74TBq/mmol) for 10 min with or without 0.1 mM
unlabeled thiamin. Incorporated [
3H]-thiamin was measured using a liquid scintillation counter. Results are expressed as mean ± SE of specific
uptake values from three independent experiments.
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Page 6 of 8encephalopathy (MIM 606152) [12], have been shown to
be associated with mutations of SLC19A3.P a t i e n t so f
BBGD with homozygous mutations (G23V, T422A) in
SLC19A3 showed childhood-onset encephalopathy, char-
acterized by epilepsy, confusion, external ophthalmople-
gia, dysarthria, dysphagia, dystonia, rigidity and
quadriparesis. In these patients, the administration of
high doses of biotin (5-10 mg/kg/day) early in the pro-
gression of the disorder eliminated their symptoms,
whereas thiamin was ineffective [10,11]. Recently, com-
pound heterozygous mutations (E320Q, K44E) in
SLC19A3 were shown to cause Wernicke’s-like encepha-
lopathy, which is characterized by acute onset of epi-
lepsy, ataxia, nystagmus and ophthalmoplegia in the
second decade of life, and symptoms are effectively alle-
viated with thiamin treatment [12].
D e s p i t es h a r i n go n em u t a n ta l l e l e( E 3 2 0 Q )w i t ht h e
known causative mutations in Wernicke’s-like encepha-
lopathy, our patients clearly differed in age at onset,
brain MRI findings and symptoms, raising the possibility
that the functions altered by the mutant SLC19A3 with
K44E are substantially different (Table 1). Although
both the BBGD phenotype and our patients showed
similar bilateral basal ganglia lesions in the brain and
encephalopathy that are fatal unless treated, the clinical
presentations of our patients are distinct from the pre-
viously reported BBGD phenotype in the following ways:
(1) epileptic spasms appeared in infancy in all of our
patients, in contrast to the epilepsy onset in childhood
for patients with BBGD; (2) MRI findings in our patients
are characterized by progressive brain atrophy and addi-
tional lesions in the bilateral thalami that are not
observed in patients with BBGD; (3) our patients did
not display obvious dystonia and cogwheel rigidity
reflecting dysfunctions in basal ganglia; (4) administra-
tion of a high dose of biotin for one year improved
neither the neurological symptoms nor the brain MRI
findings in Patient V-6, though it is unclear whether
administration of biotin at early stages of the disorder
(e.g., when epileptic spasms first appeared) improved the
subsequent clinical trajectory (Table 1). Thus our cases
broaden the phenotypic spectrum of disorders asso-
ciated with mutations in SLC19A3.
Recently, two novel mutations, both of which created
premature stop codons, were identified in BBGD
patients [16]. Transfection studies demonstrated that
G23V and T422A mutations identified in the BBGD
phenotype lead to mutant SLC19A3 that is nonfunc-
tional for thiamin uptake activity [8]. These findings
suggest that loss-of-function mutations in SLC19A3 are
associated with the BBGD phenotype. In contrast to
these loss-of-function mutations, we demonstrated that
mutant SLC19A3 with E320Q possesses some thiamin
uptake activity that is approximately 60% of wild-type
SLC19A3 in CHO cells [12] and HEK293 cells
(Figure 3C). These findings alone seem difficult to
account for severe clinical presentations in our cases.
Interestingly, a previous report showed that the negative
charge at position E320 was conserved in other trans-
porters (SLC19A1, SLC19A2) and was crucial for the
formation of a salt bridge with a conserved, positively-
charged residue, K380 [8]. The homozygous mutation of
E320 may, therefore, destabilize the protein conforma-
tion and bring with more deleterious effect, including
gain-of-toxic function and/or the dramatically changed
protein structure.
In this study, the efficacy of high doses of biotin and/
or thiamin for the clinical phenotypes of our patients
has not been determined. This indicates that we have
not determined whether our patients are phenotypic
variation of “biotin-responsive” basal ganglia disease or
“biotin-unresponsive” another type of a disease. There-
fore, accumulation of genetic analysis and clinical
courses from more patients who undergo biotin and/or
thiamin treatment as well as further laboratory studies
employing cellular or mouse models will be needed to
better characterize the clinical phenotypes and biochem-
ical characteristics of the homozygous E320Q mutation
in SLC19A3.
Conclusions
The present study indicated that four Japanese patients
in a Japanese pedigree who presented with epileptic
spasms in early infancy, severe psychomotor retardation,
and characteristic brain MRI findings of progressive
brain atrophy and bilateral thalami and basal ganglia
lesions were caused by homozygous mutation (c.958G >
C, [p.E320Q]) in SLC19A3. Our cases broaden the phe-
notypic spectrum of disorders associated with SLC19A3
mutations and highlight the potential benefit of biotin
and/or thiamin treatments and the need to assess the
clinical efficacy of these treatments.
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